Psychotropic Medication in the Treatment of Developmental and Learning Disorders

download Psychotropic Medication in the Treatment of Developmental and Learning Disorders

of 64

Transcript of Psychotropic Medication in the Treatment of Developmental and Learning Disorders

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    1/64

    UCSD RCHSDMarch 24, 2009

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    2/64

    Assistant Clinical Professor,

    Dept of Psychiatry, University ofCalifornia at San Diego School ofMedicine

    Faculty, Interdisciplinary Council onDevelopmental and Learning

    Disorders

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    3/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    4/64

    ICDL Faculty minimal - review of

    clinical write ups, travel and roomfor summer institute

    NIMH/ Duke University minimal

    administrative time forpharmacogenetic research

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    5/64

    a novella on the use of medication (20 min)

    brief monograph:medication from a DIR perspective (3 min)

    fantasies and nightmaresin med-land (2 min)

    the story of a real boyand a diagnostic system (20 min)

    your stories(15 min)

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    6/64

    all slides will be posted on

    circlestretch.blogspot.comfollow the blue dot!

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    7/64

    Quick history: Magda Campbell: haloperidolhelps social learning; others:methylphenidate causes side effects withoutbenefit.

    Today: we try to treat target symptoms,carefully, based on responses in otherconditions to medications.

    Takes time to assess, and re-assess.Big issues: marketing, side effects, and

    efficacy studies.Efficiency study: CAPTN (Duke: John March,

    el al Im an et al).

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    8/64

    Most people consider meds becausethey feel stuck, maybe desperateEmergencies: aggression, depression,

    others?Lack of progress

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    9/64

    What do we want for the child?What is the meaning of the disability

    to the family and to the child?The usual wish: a meaningful life (socially, emotionally, maybe

    cognitively)Requires a plan, and medication

    alone is not a plan.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    10/64

    regulatory issues/ motor and sensory areasaddressed

    engagement and reciprocity (vs. focus on

    compliance) language/ communicationcognition/ learningdaily living skills followed by broader and

    broader areas of life skills, from school andplayground to vocational skills.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    11/64

    Are we asking too much of the child?

    Of the family?Of the school?

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    12/64

    Low Support - Low Expectation

    (neglect)

    Low Support - High Expectation

    (Just do it)

    High Support - Low Expectation

    (walking on eggshells, more andmore constrictede.g. gamers)

    High Support - HighExpectation

    (respectful coaching)

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    13/64

    Is the program adequate?

    Will they change the childs brain andactually fix it?Will they injure the child?

    What should I expect?

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    14/64

    Losing time while pulling the programtogetherDoing as much as possibleAwakenings should we go for a

    miracle?

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    15/64

    We do not know enough to say you

    really should medicateIf there is no emergency, you have

    more time to think about it

    When parents differ, it can be anopportunity for more thoughtfulplanning

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    16/64

    Are you trying to save a placement or make up for

    a bad one? Are meds a last resort or is it unethical to withhold

    them? Complete workup a must: consider EEG, labs, etc.

    along with complete history, physical, MSE, andcollateral information.

    Availability - doctor MUST stay in touch with

    family and school Rapid, large, or multiple changes are often

    problematic Grid target symptoms vs. possible meds and fill in

    possible +s & -s

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    17/64

    Easy for the treatment team to react andoveruse medications

    Side effects often create significantdifficulties, e.g., behavioral activation

    (SSRIs), increased perseveration(stimulants), sedation (someanticonvulsants, others).

    Team treatment often becomes all aboutthe medication, ignoring engagement,

    other factors.Bottom line: medication probably does nottreat core symptoms, but might create moreaffective availability, if you can avoidsignificant side effects.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    18/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    19/64

    elements of informed consent

    the process of informed consentnearly everything is experimentalwe have to track this fairly closely

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    20/64

    NAME: DOB: DATE:

    DIAGNOSIS:TARGET SYMPTOMS:

    TREATMENT PROTOCOL:ALTERNATIVE TREATMENTS DISCUSSED:POSSIBLE RESULTS OF NO TREATMENT:SIDE EFFECTS DISCUSSED:

    FDA LABELING DISCUSSED:CONSENT AND ASSENT DISCUSSED:COMMENTS/QUESTIONS/CONCERNS:

    I UNDERSTAND THIS CONSENT AND ALL HAS BEEN EXPLAINED TO ME. TREATMENT, INCLUDING USEOF MEDICATIONS IS VOLUNTARY AND I PLAN TO WORK WITH THE DOCTOR TO MAKE THE BEST USEOF THESE.

    I CONSENT TO THE TREATMENT. IF MEDICATION IS PART OF THE TREATMENT PLAN AND I WILLREQUEST THE PRODUCT INFORMATION INSERT AT THE TIME A PRESCRIPTION IS FILLED.

    _____________________ _________ ___________________ PATIENT SIGNATURE DATE PHYSICIAN

    _____________________ __________________________ PARENT/GUARDIAN (IF APPLICABLE) RELATIONSHSIP TO PATIENT.

    update to plan: date initial of responsible party

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    21/64

    Find a doctor you like and feel you canwork with

    Keep the doctor in the loopDont overwhelm the doctor with data

    Think carefully before rapid, largechanges in dose or before changingmore thing than one thing at a time.

    Respectfully offer resources dont expect

    your doctor will read a book for you, but doexpect your doctor is interested in otheropinions from other doctors

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    22/64

    Look for Basic Competence: APBNBoard Certified Child and AdolescentPsychiatrists were checked forcompetence in assessing autism, andfor use of collateral information fromfamily, school, and other

    professionals.Look for Honesty: AACAP = a

    promise to be ethical and do their

    best

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    23/64

    Helping parents determine whenmedication may be worth consideringHelping families navigate well to

    utilize their doctors and otherprovidersHelping families orchestrate the

    whole set of interventions into acoherent and manageable planGood Luck!

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    24/64

    Can Medications Help Kids HaveBetter,

    More Productive RelationshipsWith Us?

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    25/64

    Co-regulationEngagementCirclesFlowSymbolic thinkingLogical social problem solvingMulti-causal thinkingGrey area thinkingReflective thinking, stable sense of self,

    internal standard

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    26/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    27/64

    Sensory processingPostural control/ motor planningReceptive communicationExpressive communicationVisual-spatial functionPraxis: ideation, planning,

    sequencing, execution, adaptation

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    28/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    29/64

    Support regulation and co-regulation bytreating symptoms that get in the way,e.g., impulsivity, inattention, anxiety,

    rigid thinking, perseveration.Widen tolerance of affective experienceso the person is less likely to becomeoverwhelmed.

    Treat co-morbid conditions, e.g.,depression.Possibly: allow for or promote improved

    ability for abstract reasoning and

    thinking.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    30/64

    DIR is the main courseMeds are the pickles

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    31/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    32/64

    A Good Enough WizardUnpredictable Potions

    Nefarious Forces:syndromes & systems(affecting schools, social services, and industry)

    and

    transferences & countertransferences(invisible and everpresent)

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    33/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    34/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    35/64

    SeizuresWeight gainInsulin resistanceTardive DyskinesiaNeuroleptic Malignant Syndrome

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    36/64

    perseveration, anxiety, depressionmay improveoften the benefits are outweighed by

    overactivity, inattention, or evenmania, rarely seizures, and sweatingas a precursor to serotonin syndrome

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    37/64

    For mood stabilization, oh, and fewer seizures Well Mrs Farkel Liver, pancreas, weight gain,

    sedation, incontinence, drooling, and if you everwant to have babies beware of PCOS, loss of whitecells, bleeding problemss

    Tegretols blood and cardiac problems Lamictals scathing rash, and unweildy interaction

    with Depakote

    Topamax: wt loss, but language loss; unreliability,decreased sweatingOthers

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    38/64

    The plan that lived, due to betterfocus and less overactivityRagged sleep, ratty moods, thin waifs

    with sunken eyes, stupors, tics, andoccasional paranoia; cardiac andgrowth issues

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    39/64

    Reliable anxiolytic, helpful forseizuresReliable loss of memory and motor

    control, with inability to benefit fromlearning and high risk of falling andautomobile accidents

    Addiction is rampantALL MEMBERS OF THIS CLASS

    (BENZODIAZEPINES) ARE

    PROBLEMATIC

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    40/64

    The number one cause of death byantidepressants due to overdose in thedays before SSRIs

    CARDIOTOXIC: have people LOCK THEMUP! and get serial EKGs w/ Cardiologistreadings

    Still, they are as effective or more effectivethan any other antidepressants we have,and clomipramine is more effective,generally than SSRIs for OCD.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    41/64

    Find a good enough Wizard, one whoknows the stories, good and bad, andwho listens to you and your people

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    42/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    43/64

    case synopsisvideo clipsanalysisdiscussion

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    44/64

    K Searcy - ?Meds for anxiety in

    autism, Jan 2008Failure to make gains despitemassive services

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    45/64

    AutismSAFETY fingers in eyesextremely perseverative (fans)

    anxietyover-activitytantrums language

    hard to take him out, (esp. dad)?seizures.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    46/64

    planned C/S at 39 wk., mild jaundice, WBC up but ok. constantly nursing, mom w/o sleep. crawled 9 mo, walked 11 mo words at 12 mo but slow to gain new ones and they didnt

    stick well

    13 mo: sudden stimming, classic ASD,but still cuddling

    FH: sister PDDNOS now better, cousin ASD; others:anxiety, OCD

    Sp Ed PK and CARES then ACES, Crimson, etc. medical: ?Sz, allergies to eggs, peanuts, amox, eczema

    Medicationss: Trileptal, EEG improved;Spring 08 Citalopram at 10 mg helps

    anxiety; Fall 08 Metadate CD 15 mg.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    47/64

    break the door MOV00732.MPG(0:10)Malingo Toya song and dance (0:55)This Little Piggy (4:50)

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    48/64

    Axis I Primary DiagnosisAxis II - Functional Emotional

    Developmental Capacities

    Axis IIIRegulatorySensory ProcessingCapacities

    AxisIVLanguage CapacitiesAxisVVisuospatial Capacities

    AxisVIChildCaregiver and Family PatternsAxisVIIStress

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    49/64

    Axis I Primary Diagnosis

    Axis II - Functional EmotionalDevelopmental Capacities

    Axis IIIRegulatorySensory Processing Capacities AxisIVLanguage Capacities AxisVVisuospatial Capacities AxisVIChildCaregiver and Family Patterns AxisVIIStress

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    50/64

    Notthere

    Barely Islands Expands

    Comesback

    Ok ifnotstressed

    Ok forage

    Co-regulate

    3/08 9/08 3/09

    Engage 3/08 9/08 3/09

    Circles 3/08 9/08 3/09

    Flow 3/08 9/08 3/09

    Symbolic 3/08 9/08, 3/09

    Logical3/08,3/07,3/08

    Multicausal

    3/08,3/07,3/08

    Grey area 3/08,3/07,3/08

    Reflective 3/08,3/07,3/08

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    51/64

    03/08 moments ofgleam and a couple of circleswhen I get playfully in his way unplug the fan orstop him from crawling under my desk

    09/08 - join and shift the OC on AC to ram intocouch; shift OC on AC to blanket fan; fishing for feet flow; malingo toya making a song somewhat symbolic

    3/09 calmer and able to cuddle nearly the whole session

    with mom, makes possible coaching mom for moreelaboration of circles and some flow with her; can talk abouttoes, but not really more symbolic per se.

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    52/64

    Axis I Primary Diagnosis Axis II - Functional Emotional Developmental Capacities

    Axis IIIRegulatorySensory

    Processing CapacitiesAxis IVLanguage CapacitiesAxis VVisuospatial Capacities AxisVIChildCaregiver and Family Patterns

    AxisVIIStress

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    53/64

    Sensory

    Postural Response toCommunication

    Intent toCommunicate

    VisualExploration

    Praxis -

    Sensory

    seeking,distractible

    Auditory

    Visual

    Tactile

    Vestibular

    Proprio-

    ceptive

    Taste

    Odor

    Best when core is

    supported

    1 indicate desires

    ----3/08----

    2. mirror gestures

    3. imitate gesture

    4. Imitate withpurpose.

    ----9/08----5. Obtain desires6. interact:- exploration-purposeful

    ----3/09----

    - self help

    -interactions

    Cues into important

    words

    Orient

    ----3/08----

    2. key tones3. key gestures

    4. key words

    ----9/08----5. Switch auditoryattention back andforth6. Follow directions7. Understand W ?s ----3/09----8.abstractconversation.

    Often

    unintelligible

    Mirrorvocalizations ----3/08----

    2.. Mirrorgestures

    3. gestures

    4. sounds

    5.words----9/08----

    6. two word

    7. Sentences----3/09----

    8. logical flow.

    Spots fans at distance;

    fingers in eyes; rare

    gleam

    focus on object

    ----3/08----

    2. Alternate gaze3. Follow

    anothers gazeto determineintent.3. Switch visualattention----9/08----4. visual figureground5. search forobject----3/09----

    6. search twoareas of room7. assess space,shape andmaterials.

    Perseverative

    ideas; canexpand w/support

    Ideation----3/08----

    Planning(including

    sensoryknowledge to dothis)----9/08----

    Sequencing----3/09----

    Execution

    Adaptation

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    54/64

    Axis I Primary Diagnosis Axis II - Functional Emotional Developmental Capacities Axis IIIRegulatorySensory Processing Capacities AxisIVLanguage Capacities AxisVVisuospatial Capacities

    AxisVIChildCaregiver and FamilyPatternsAxisVIIStress

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    55/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    56/64

    Axis I Primary Diagnosis Axis II - Functional Emotional Developmental Capacities Axis IIIRegulatorySensory Processing Capacities AxisIVLanguage Capacities AxisVVisuospatial Capacities AxisVIChildCaregiver and Family Patterns AxisVIIStress

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    57/64

    100. Interactive Disorders 200. Regulatory Sensory Processing Disorders

    300. Neurodevelopmental

    Disorders of Relating andCommunicating 400. Language Disorders 500. Learning Challenges

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    58/64

    300.1 Type I:Early Symbolic, with Constrictions ; intermittent capacity for attending,relating, reciprocal social interaction, including social problem solving, and beginning use of

    meaningful ideasmakesrapid progress in a comprehensive program

    300.2 Type II:Purposeful Problem Solving, with Constrictions; as above but only

    fleeting social problem solvingtend to make steady, methodicalprogress

    300.3 Type III: Intermittantly Engaged and Purposeful; only fleeting attention andengagement, occasional reciprocal social interaction with lots of support slow,

    steady progress possible, maybe with gradual use of words or phrases 300.4 Type IV: Aimless and Unpurposful;multiple regressions, maybe more

    neurologic challenges, very very slow progress

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    59/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    60/64

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    61/64

    Mar 08: we are in a dangerous crisis dysregulatedand perseverative

    Sept 08: with meds and direction to the intervention,

    he can be entrained into collaborativeinteractionMar 09: we are confident that with coaching

    his capacities will expand

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    62/64

    Medication management, and moreGuiding the whole team, once and

    twice removed.As the prescribing physician I have

    responsibility, accountability, andleverage - they come back

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    63/64

    Will you be careful with the meds?

    Will you look at the whole picture?Will you continue to learn and

    explore?

  • 8/14/2019 Psychotropic Medication in the Treatment of Developmental and Learning Disorders

    64/64